The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients

Christoph C Zielinski, Ahmad Awada, David A Cameron, Tanja Cufer, Miguel Martin, Matti Aapro

Research output: Contribution to journalArticlepeer-review

Abstract

Febrile neutropenia (FN) is a severe consequence of myelosuppressive therapy. The European Organisation for Research and Treatment of Cancer recently published guidelines on the use of granulocyte colony-stimulating factor (G-CSF) to prevent FN in patients with malignant disease. In this review, the impact of these guidelines on breast cancer treatment is discussed. A brief summary of FN in breast cancer is given, and patient-related and treatment schedule-related risk factors for FN are reviewed for the adjuvant/neoadjuvant and metastatic disease settings. Primary G-CSF support is recommended if the overall FN risk is > or = 20%, or if a reduction in dose-intensity is associated with a poorer outcome. Any formulation of G-CSF is recommended. The utility of G-CSF in reducing the incidence of FN and enabling treatment regimens is discussed.
Original languageEnglish
Pages (from-to)353-65
Number of pages13
JournalEur J Cancer
Volume44
Issue number3
DOIs
Publication statusPublished - 2008

Keywords

  • Aged
  • Antineoplastic Agents
  • Breast Neoplasms
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Evidence-Based Medicine
  • Female
  • Granulocyte Colony-Stimulating Factor
  • Humans
  • Middle Aged
  • Neutropenia
  • Practice Guidelines as Topic
  • Risk Assessment
  • Risk Factors
  • Treatment Outcome

Fingerprint

Dive into the research topics of 'The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients'. Together they form a unique fingerprint.

Cite this